Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5WFC

Humanized mutant of the Chaetomium thermophilum Polycomb Repressive Complex 2 bound to the inhibitor GSK343

5WFC の概要
エントリーDOI10.2210/pdb5wfc/pdb
関連するPDBエントリー5WF7
分子名称Polycomb Protein EED, Histone-lysine-N-methyltransferase EZH2, Polycomb protein SUZ12 chimera, Histone H3.1, ... (6 entities in total)
機能のキーワードtransferase, inhibitor, complex, epigenetics, transferase-transferase inhibitor complex, transferase/transferase inhibitor
由来する生物種Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719)
詳細
タンパク質・核酸の鎖数3
化学式量合計175034.35
構造登録者
Bratkowski, M.A.,Liu, X. (登録日: 2017-07-11, 公開日: 2018-06-27, 最終更新日: 2023-10-04)
主引用文献Bratkowski, M.,Yang, X.,Liu, X.
An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors.
Sci Rep, 8:9092-9092, 2018
Cited by
PubMed Abstract: Polycomb repressive complex 2 (PRC2) mediates trimethylation of histone H3K27 (H3K27me3), an epigenetic hallmark for repressed chromatin. Overactive mutants of the histone lysine methyltransferase subunit of PRC2, Ezh2, are found in various types of cancers. Pyridone-containing inhibitors such as GSK126 compete with S-adenosylmethionine (SAM) for Ezh2 binding and effectively inhibit PRC2 activity. PRC2 from the thermophilic fungus Chaetomium thermophilum (ct) is functionally similar to the human version in several regards and has the added advantage of producing high-resolution crystal structures, although inhibitor-bound structures of human or human/chameleon PRC2 are also available at up to 2.6 Å resolution. We solved crystal structures of both human and ctPRC2 bound to GSK126 and the structurally similar inhibitor GSK343. While the two organisms feature a disparate degree of inhibitor potency, surprisingly, GSK126 binds in a similar manner in both structures. Structure-guided protein engineering of the drug binding pocket allowed us to introduce humanizing mutations into ctEzh2 to produce a ctPRC2 variant that is more susceptible to GSK126 inhibition. Additional analysis indicated that an evolutionarily conserved structural platform dictates a unique mode of GSK126 binding, suggesting a mechanism of drug selectivity. The existing drug scaffold may thus be used to probe the function and cellular regulation of PRC2 in a wide spectrum of organisms, ranging from fungi to humans.
PubMed: 29904056
DOI: 10.1038/s41598-018-27175-w
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.282 Å)
構造検証レポート
Validation report summary of 5wfc
検証レポート(詳細版)ダウンロードをダウンロード

248335

件を2026-01-28に公開中

PDB statisticsPDBj update infoContact PDBjnumon